A genetic compensation response model for RIG loss.

(A) Loss of RIG-I in vertebrates. Each branch tip represents one species. Red lines show lineages where loss of RIG-I. The red circle indicates the occurrence of an independent loss event. Branch lengths scale in millions of years (MYA). (B) Comparative analysis of gene synteny of RIG-I in vertebrate genomes. (C) Predicted protein structures of MDA5 and LGP2 in M. miiuy. (D) A genetic compensation response model for RIG loss.

MDA5 promotes host antiviral innate immunity.

(A) Silence efficiency of si-MDA5 measured by qRT-PCR and Western blotting. Two siRNAs of MDA5 were transfected into MPC cells for 48 h respectively. (B) subcellular localization of MDA5 in MKCs by immunofluorescence. (C and D) MDA5 immunoprecipitates with MAVS (C) and STING (D). EPC cells (1×107) were co-transfected with MAVS-Myc or STING-Myc and MDA5-Flag expression plasmids for 24 h, followed by immunoprecipitation (IP) with anti-Myc. (E) MDA5 knockdown suppresses NF-κB, IRF3, IRF7, and IFN-1 signaling. MPC cells were transfected with pRL-TK Renilla luciferase plasmid, luciferase reporter genes, together with MDA5 expression plasmid. At 48 h post-transaction, the luciferase activity was measured and normalized to renilla luciferase activity. (F) Knockdown of MDA5 attenuates the expression of antiviral genes. MPC cells were transfected with si-Ctrl or si-MDA5 for 24 h and then treated with SCRV or poly (I:C) for 24 h. The expression of IFN-1, Mx1, ISG15, and Viperin expression were determined by qPCR. (G and H) Overexpression of MDA5 promotes the expression of antiviral genes. MKC cells were transfected with vector or MDA5 expression plasmid for 24 h and then treated with SCRV or poly (I:C) for 24 h. The expression of MDA5(G), and antiviral genes, including IFN-1, Mx1, ISG15, and Viperin (H) were determined by qPCR. (I and K) MPC cells transfected with si-Ctrl or si-MDA5 and MKC cells transfected with pcDNA3.1 vector or MDA5 plasmid 24 h and then treated with SCRV at the dose indicated for 48 h. Then, cell monolayers were fixed with 4% paraformaldehyde and stained with 1% crystal violet. (J and L) MDA5 inhibits SCRV replication. MPC cells were transfected with si-Ctrl or si-MDA5 and MKC cells were transfected with pcDNA3.1 vector or MDA5 expression plasmid for 24 h, then infected with SCRV for 12, 24, or 48 h. The qPCR analysis was conducted for SCRV-M and SCRV-G RNA levels. All data presented as the means ± SE from at least three independent triplicated experiments. **, p < 0.01; *, p < 0.05 versus the controls.

RD domain is required for MDA5 to recognize SCRV.

(A) The association of MDA5 proteins with SCRV. (B) Schematics and expression of MDA5 and truncated MDA5 (MDA5-△ RD). (C) The association of MDA5 and MDA5-△RD proteins with SCRV. (D) MKC cells transfected with pcDNA3.1 vector, MDA5, or MDA5-△RD plasmids for 24 h and then treated with SCRV at the dose indicated for 48 h. Then, cell monolayers were fixed with 4% paraformaldehyde and stained with 1% crystal violet. (E) MKC cells were transfected with pcDNA3.1 vector, MDA5 or MDA5-△RD expression plasmids for 24 h, then infected with SCRV for 24 h, then the qPCR analysis was conducted for SCRV-M and SCRV-G RNA levels. (F and G) Expression of MDA5 and antiviral genes in uninfected or SCRV-infected MKC cells transfected with pcDNA3.1 vector, MDA5, or MDA5-△RD expression plasmids. All data presented as the means ± SE from at least three independent triplicated experiments. **, p < 0.01; *, p < 0.05 versus the controls.

MDA5 recognize 5’ppp-RNA in vertebrates lacking RIG-I.

(A) Schematic representation of 5’ppp-RNA and dsRNA. The product of in vitro transcription runs as a single product degraded by RNase I. (B) Pulldown of dsRNA and 5’ppp-RNA by mmiMDA5. MKC cells were transfected with mmiMDA5-Flag plasmid, and the input and immunoprecipitated MDA5 proteins were analyzed by Coomassie bluestaining and Western blot. (C) The cytoplasmic fraction of MKC cells transfected with Flag-tagged mmiMDA5 was incubated with biotinylated 5’ppp-RNA, 5’OH-RNA (5’ppp-RNA dephosphorylated by CIAP), or 5’pppGG-RNA (5’ppp-RNA capped by m7G cap analog). RNA-protein complexes were pulled down using streptavidin affinity beads. Input and pull-down samples were analyzed by SDS-PAGE and immunoblotting using anti-Flag and anti-MDA5 antibody. (D) Purity of recombinant mmiMDA5 was determined by Coomassie bluestaining. (E) EMSA of 5’ppp-RNA with mmiMDA5. For binding competition, indicated unlabeled RNAs (50-fold molar excess over the probe) were included. (F) Pulldown of dsRNA and 5’ppp-RNA by ggaMDA5. DF-1 cells were transfected with ggaMDA5-Flag plasmid, and the input and immunoprecipitated MDA5 proteins were analyzed by Western blot. (G) The cytoplasmic fraction of DF-1 cells transfected with Flag-tagged ggaMDA5 was incubated with biotinylated 5’ppp-RNA, 5’OH-RNA (5’ppp-RNA dephosphorylated by CIAP), or 5’pppGG-RNA (5’ppp-RNA capped by m7G cap analog). RNA-protein complexes were pulled down using streptavidin affinity beads. Input and pull-down samples were analyzed by SDS-PAGE and immunoblotting using anti-Flag antibody. (H) EMSA of 5’ppp-RNA with ggaMDA5. For binding competition, indicated unlabeled RNAs (50-fold molar excess over the probe) were included.

Increased m6A modification and expression of MDA5 upon SCRV infection.

(A) Schematic of the MeRIP-seq protocol used to identify differential m6A methylation following infection of M. miiuy spleen tissues with SCRV. (B) Circos plots showing differentially m6A-methylated peaks identified from normal and SCRV-infected spleen tissues of M. miiuy. The green and red lines on the innermost ring represented the m6A peaks identified from normal and SCRV-infected spleen tissues of M. miiuy respectively. The orange lines represent the log2 fold change values for each differentially m6A peak. The blue spots represent the fold change of gene expression. Chromosomes were shown on the outermost ring, the ruler on which represented the physical distance is in millions of bases (Mb). (C) The m6A abundance in MDA5 mRNA transcripts detected by MeRIP-seq, the m6A peak of MDA5 is circled in the green box. (D) The exon1 sequence of MDA5 was submitted to the SRAMP website, and then the predicted m6A site was displayed. Four predicted methylation sites located on the exon1 of MDA5 were marked by red box, then we designed two m6A specific primers (MDA5-m6A-1 and MDA5-m6A-2). (E) m6A abundance on MDA5 exon1 detected by MeRIP-qPCR and emiquantitative PCR in MKC cells. (F) MeRIP-qRT-PCR analysis of relative m6A level of MDA5 in Mock, SCRV, and poly(I:C)-infected MKC cells. (G) mRNA levels of MDA5 in spleen and kidney tissues measured by qRT-PCR at indicated time after SCRV and infection. (H and I) mRNA and protein levels of MDA5 in MKC cells measured by qRT-PCR and Western blotting at indicated time after SCRV (H) and poly(I:C) (I) infection. All data presented as the means ± SE from at least three independent triplicated experiments. **, p < 0.01 versus the controls.

m6A-modification weakens MDA5 mRNA stability and antiviral ability.

(A) Silence efficiency of si-METTL3 and si-METTL14 measured. Three siRNAs of METTL3 and METTL14 were transfected into MPC cells for 48 h respectively. (B) METTL3 immunoprecipitates with METTL14. EPC cells (1×107) were co-transfected with METTL3-Myc and METTL14-Flag expression plasmids for 24 h, followed by immunoprecipitation (IP) with anti-Myc. (C) METTL3 and METTL14 significantly increased the m6A content. MPCs were transfected with si-Ctrl or si-METTL3 or si-METTL14 and MKCs were transfected with vector or METTL3 or METTL14 plasmids for 48 h, then the m6A level was measured by colorimetry. (D) METTL3 and METTL14 overexpressed MKC cells seeded in 48-well plates overnight were treated with SCRV at the dose indicated for 48 h. Then, cell monolayers were fixed with 4% paraformaldehyde and stained with 1% crystal violet. (E) MKC cells were transfected with pcDNA3.1 vector and METTL3 or METTL14 expression plasmid for 24 h, then infected with SCRV for 24 h. The qPCR analysis was conducted for SCRV-M and SCRV-G RNA levels. (F) The m6A level alteration of MDA5 upon METTL3 or METTL14 knockdown or overexpression was examined by MeRIP-qPCR. MPC cells were transfected with si-Ctrl or si-METT3 and MKC cells were transfected with vector or METTL3 or METTL14 plasmids for 48 h. (G and H) MPC cells were transfected with si-Ctrl, si-METTL3 or METTL14 and MKC cells were transfected with vector, METTL3, or METTL14 plasmids for 48 h, the expression of MDA5 was detected by qRT-PCR and Western blotting. (I) MPC cells were transfected with si-Ctrl, si-METTL3, or si-METTL14, and MKC cells were transfected with vector, METTL3, or METTL14 plasmids, then 5 µg/ml actinomycin D was added to the cells for 0 h, 2 h, and 4 h. The half-life of MDA5 was analyzed by qRT-PCR. (J) MKC cells were transfected with vector or METTL3&14 plasmids for 24 h and then treated with Cycloleucine (CL) for 24 h in a final concentration of 20 mM. The expression of MDA5 was detected by qRT-PCR and Western blotting. (K) MKC cells were transfected with vector or METTL3&14 plasmids for 24 h and then treated with CL for 24 h at 20 mM, then 5 µg/ml actinomycin D was added to the cells for 0 h, 2 h, and 4 h. The half-life of MDA5 was analyzed by qRT-PCR. (L) MKC cells were transfected with vector or METTL3&14 plasmids for 24 h and stimulated with SCRV for 24 h, then the expression of MDA5 was detected by qRT-PCR and Western blotting. (M) MKC cells seeded in 48-well plates overnight were transfected with MDA5 or MDA5+METTL3&14 plasmids for 48 h, then the expression of MDA5 was detected by qRT-PCR and Western blotting. (N) MKC cells seeded in 48-well plates overnight were transfected with MDA5 or MDA5+METTL3&14 plasmids were treated with SCRV at the dose indicated for 48 h. Then, cell monolayers were fixed with 4% paraformaldehyde and stained with 1% crystal violet. (O) MKC cells were transfected with MDA5 or MDA5 + METTL3&14 plasmids for 24 h, then infected with SCRV for 24 h. The qPCR analysis was conducted for SCRV-M and SCRV-G RNA levels. All data presented as the means ± SE from at least three independent triplicated experiments. **, p < 0.01; *, p < 0.05 versus the controls.

Detailed m6A regulatory mechanism of MDA5.

(A) The binding relationship between YTHDF1, YTHDF2, or YTHDF3 and MDA5 mRNA was validated using a RIP assay. MKC cells were transfected with YTHDF1-Flag, YTHDF2-Flag, YTHDF3-Flag, or pcDNA3.1-Flag for 48 h. (B) SiRNA silencing effect test of YTHDF1, YTHDF2, and YTHDF3. MPC cells were transfected with si-YTHDF1, si-YTHDF2, or si-YTHDF3 for 48 h. (C and D) MPC cells were transfected with si-YTHDF1, si-YTHDF2, si-YTHDF3 or si-Ctrl (C), and MKC cells were transfected with YTHDF1, YTHDF2, YTHDF3 or vector for 48 h (D), then the expression of MDA5 was detected by qRT-PCR and Western blotting. (E) Relative mRNA and protein levels of MDA5 in MKC cells after co-transfected with YTHDF2&3 plasmids and si-METTL3&14 by qPCR and western blot assays. (F) MKC cells were transfected with YTHDF2&3 plasmids and si-METTL3&14, then 5 µg/ml actinomycin D was added to the cells for 0 h, 2 h, and 4 h. The half-life of MDA5 was analyzed by qRT-PCR. (G) MKC cells were transfected with vector, FTO, ALKBH5 plasmids for 48 h, then the expression of MDA5 was detected by qRT-PCR and Western blotting. (H) Relative mRNA and protein levels of MDA5 in MKC cells after co-transfected with YTHDF2&3 plasmids and FTO plasmids by qPCR and western blotting. (I) MKC cells were transfected with YTHDF2&3 plasmids and FTO plasmids, then 5 µg/ml actinomycin D was added to the cells for 0 h, 2 h, and 4 h. The half-life of MDA5 was analyzed by qRT-PCR. (J) Schematic diagram of arms race between MDA5 and 5’ppp-RNA.